

Martina Amanzio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3594597/publications.pdf>

Version: 2024-02-01

66
papers

5,623
citations

147801

31
h-index

114465

63
g-index

68
all docs

68
docs citations

68
times ranked

3670
citing authors

#	ARTICLE	IF	CITATIONS
1	Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review. <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100253.	5.6	46
2	How do nocebo effects in placebo groups of randomized controlled trials provide a possible explicative framework for the COVID-19 pandemic?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 439-444.	3.1	12
3	Investigating Neuroimaging Correlates of Early Frailty in Patients With Behavioral Variant Frontotemporal Dementia: A MRI and FDG-PET Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 637796.	3.4	6
4	The Role of Neuropsychological Factors in Perceived Threat of SARS-CoV-2 in Healthy Ageing. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5847.	2.6	6
5	Lockdown Effects on Healthy Cognitive Aging During the COVID-19 Pandemic: A Longitudinal Study. <i>Frontiers in Psychology</i> , 2021, 12, 685180.	2.1	26
6	Editorial: Physical and Cognitive Frailty in the Elderly: An Interdisciplinary Approach. <i>Frontiers in Psychology</i> , 2021, 12, 698819.	2.1	2
7	Hypothalamicâ€Pituitaryâ€Adrenal Activity in Adverse Events Reporting After Placebo Administration. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1349-1357.	4.7	4
8	Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. <i>Vaccines</i> , 2021, 9, 1179.	4.4	7
9	Are Sleep Problems Related to Psychological Distress in Healthy Aging during the COVID-19 Pandemic? A Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10676.	2.6	8
10	A Possible Association Between Executive Dysfunction and Frailty in Patients With Neurocognitive Disorders. <i>Frontiers in Psychology</i> , 2020, 11, 554307.	2.1	11
11	Reduced Self-Awareness Following a Combined Polar and Paramedian Bilateral Thalamic Infarction. A Possible Relationship With SARS-CoV-2 Risk of Contagion?. <i>Frontiers in Psychology</i> , 2020, 11, 570160.	2.1	3
12	How Do Nocebo Phenomena Provide a Theoretical Framework for the COVID-19 Pandemic?. <i>Frontiers in Psychology</i> , 2020, 11, 589884.	2.1	26
13	Executive Dysfunction and Reduced Self-Awareness in Patients With Neurological Disorders. A Mini-Review. <i>Frontiers in Psychology</i> , 2020, 11, 1697.	2.1	19
14	Editorial: Unawareness of Illness in Neurological Disorders: A Focussed Neurocognitive Approach Shedding Light on Neuropsychological Deficits and Neural Underpinnings Potential Association. <i>Frontiers in Psychology</i> , 2020, 11, 622576.	2.1	1
15	Editorial: Nocebo Effects and Their Influence on Clinical Trials and Practice: Modulating Factors in Healthy and Pathological Conditions. <i>Frontiers in Pharmacology</i> , 2020, 11, 100.	3.5	5
16	Nocebo effects and psychotropic drug action - an update. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 75-77.	3.1	2
17	Pain Anticipation and Nocebo-Related Responses: A Descriptive Mini-Review of Functional Neuroimaging Studies in Normal Subjects and Precious Hints on Pain Processing in the Context of Neurodegenerative Disorders. <i>Frontiers in Pharmacology</i> , 2019, 10, 969.	3.5	7
18	A novel neurocognitive approach for placebo analgesia in neurocognitive disorders. <i>Experimental Gerontology</i> , 2019, 118, 106-116.	2.8	5

#	ARTICLE	IF	CITATIONS
19	Are Patients With Schizophrenia Spectrum Disorders More Prone to Manifest Nocebo-Like-Effects? A Meta-Analysis of Adverse Events in Placebo Groups of Double-Blind Antipsychotic Trials. <i>Frontiers in Pharmacology</i> , 2019, 10, 502.	3.5	11
20	Role of the Cingulate Cortex in Dyskinesias-Reduced-Self-Awareness: An fMRI Study on Parkinson's Disease Patients. <i>Frontiers in Psychology</i> , 2018, 9, 1765.	2.1	25
21	Neuropsychological correlates of instrumental activities of daily living in neurocognitive disorders: a possible role for executive dysfunction and mood changes. <i>International Psychogeriatrics</i> , 2018, 30, 1871-1881.	1.0	22
22	Corrigendum to "Neural correlates of reduced awareness in instrumental activities of daily living in frontotemporal dementia" [Exp. Gerontol. 83 (2016) 158-164]. <i>Experimental Gerontology</i> , 2017, 96, 164-165.	2.8	4
23	A novel framework for understanding reduced awareness of dyskinesias in Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2017, 39, 58-63.	2.2	20
24	Neuropsychological Correlates of Pre-Frailty in Neurocognitive Disorders: A Possible Role for Metacognitive Dysfunction and Mood Changes. <i>Frontiers in Medicine</i> , 2017, 4, 199.	2.6	22
25	Conceptualizing Placebo as Active Component and Adjunct in Psychological Treatment. , 2016, , .		0
26	Nocebo and Pain. , 2016, , 117-131.		3
27	Neural correlates of reduced awareness in instrumental activities of daily living in frontotemporal dementia. <i>Experimental Gerontology</i> , 2016, 83, 158-164.	2.8	19
28	Lessons Learned From Nocebo Effects in Clinical Trials for Pain Conditions and Neurodegenerative Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 475-482.	1.4	14
29	Experimental pain processing in individuals with cognitive impairment. <i>Pain</i> , 2015, 156, 1396-1408.	4.2	85
30	Nocebo vs. Placebo: The Challenges of Trial Design in Analgesia Research. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 143-150.	4.7	44
31	Unawareness of bipolar disorder: the role of the cingulate cortex. <i>Neurocase</i> , 2015, 21, 438-447.	0.6	15
32	Pain anticipation: An activation likelihood estimation meta-analysis of brain imaging studies. <i>Human Brain Mapping</i> , 2015, 36, 1648-1661.	3.6	113
33	Nocebo effects and psychotropic drug action. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 159-161.	3.1	12
34	Pain in Parkinson Patients. , 2015, , 209-219.		0
35	Unawareness of deficits in ischemic injury: Role of the cingulate cortex. <i>Neurocase</i> , 2014, 20, 540-555.	0.6	18
36	Self-unawareness of levodopa induced dyskinesias in patients with Parkinson's disease. <i>Brain and Cognition</i> , 2014, 90, 135-141.	1.8	34

#	ARTICLE	IF	CITATIONS
37	The magnitude of nocebo effects in pain: A meta-analysis. <i>Pain</i> , 2014, 155, 1426-1434.	4.2	154
38	Activation likelihood estimation meta-analysis of brain correlates of placebo analgesia in human experimental pain. <i>Human Brain Mapping</i> , 2013, 34, 738-752.	3.6	165
39	Mechanisms of the placebo response. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 520-523.	2.6	78
40	Impaired Awareness of Deficits in Alzheimer's Disease: The Role of Everyday Executive Dysfunction. <i>Journal of the International Neuropsychological Society</i> , 2013, 19, 63-72.	1.8	50
41	A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment. <i>International Psychogeriatrics</i> , 2012, 24, 698-707.	1.0	22
42	Shared "Core" Areas between the Pain and Other Task-Related Networks. <i>PLoS ONE</i> , 2012, 7, e41929.	2.5	59
43	Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. <i>Nature Medicine</i> , 2011, 17, 1228-1230.	30.7	248
44	Unawareness of deficits in Alzheimer's disease: role of the cingulate cortex. <i>Brain</i> , 2011, 134, 1061-1076.	7.6	124
45	The placebo response: How words and rituals change the patient's brain. <i>Patient Education and Counseling</i> , 2011, 84, 413-419.	2.2	118
46	Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors. <i>Psychopharmacology</i> , 2011, 213, 791-797.	3.1	57
47	Do we Need a New Procedure for the Assessment of Adverse Events in Anti-migraine Clinical Trials?. <i>Recent Patents on CNS Drug Discovery</i> , 2011, 6, 41-47.	0.9	16
48	Impaired awareness of movement disorders in Parkinson's disease. <i>Brain and Cognition</i> , 2010, 72, 337-346.	1.8	53
49	A systematic review of adverse events in placebo groups of anti-migraine clinical trials. <i>Pain</i> , 2009, 146, 261-269.	4.2	199
50	Metaphor comprehension in Alzheimer's disease: Novelty matters. <i>Brain and Language</i> , 2008, 107, 1-10.	1.6	97
51	The Biochemical and Neuroendocrine Bases of the Hyperalgesic Nocebo Effect. <i>Journal of Neuroscience</i> , 2006, 26, 12014-12022.	3.6	359
52	Response variability to analgesics: a role for non-specific activation of endogenous opioids. <i>Pain</i> , 2001, 90, 205-215.	4.2	357
53	Response expectancies in placebo analgesia and their clinical relevance. <i>Pain</i> , 2001, 93, 77-84.	4.2	360
54	Quantitative EEG Responses to Ischaemic Arm Stress in Migraine. <i>Cephalalgia</i> , 2001, 21, 224-229.	3.9	14

#	ARTICLE	IF	CITATIONS
55	Neuropharmacological Dissection of Placebo Analgesia: Expectation-Activated Opioid Systems versus Conditioning-Activated Specific Subsystems. <i>Journal of Neuroscience</i> , 1999, 19, 484-494.	3.6	781
56	Somatotopic Activation of Opioid Systems by Target-Directed Expectations of Analgesia. <i>Journal of Neuroscience</i> , 1999, 19, 3639-3648.	3.6	323
57	Inducing placebo respiratory depressant responses in humans via opioid receptors. <i>European Journal of Neuroscience</i> , 1999, 11, 625-631.	2.6	113
58	Neurophysiologic assessment of nerve impairment in posterolateral and muscle-sparing thoracotomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1998, 115, 841-847.	0.8	189
59	Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. <i>Pain</i> , 1998, 74, 205-211.	4.2	123
60	The specific effects of prior opioid exposure on placebo analgesia and placebo respiratory depression. <i>Pain</i> , 1998, 75, 313-319.	4.2	70
61	Control of Postoperative Pain by Transcutaneous Electrical Nerve Stimulation After Thoracic Operations. <i>Annals of Thoracic Surgery</i> , 1997, 63, 773-776.	1.3	148
62	Postoperative Pain and Superficial Abdominal Reflexes After Posterolateral Thoracotomy. <i>Annals of Thoracic Surgery</i> , 1997, 64, 207-210.	1.3	93
63	THE NEUROBIOLOGY OF PLACEBO ANALGESIA: FROM ENDOGENOUS OPIOIDS TO CHOLECYSTOKININ. <i>Progress in Neurobiology</i> , 1997, 52, 109-125.	5.7	214
64	Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. <i>Pain</i> , 1997, 71, 135-140.	4.2	183
65	Potentiation of placebo analgesia by proglumide. <i>Lancet, The</i> , 1995, 346, 1231.	13.7	183
66	Nocebo-Prone Behavior Contributes to SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1